Natixis’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
Natixis's BMY Position: Q2 2026 in Review
Natixis increased its Bristol-Myers Squibb (BMY) stake by 22% in Q2 2026, buying an estimated $25.9M and bringing the position to 2,519,137 shares worth $145M. The position accounts for 0.58% of the portfolio, ranked #25.
Natixis first reported a position in BMY in Q2 2013 and has held it in 45 quarters since. The position peaked at $436M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Natixis held 2,519,137 shares of Bristol-Myers Squibb worth $145M as of Q2 2026.
- Natixis bought 451,073 Bristol-Myers Squibb shares in Q2 2026, an estimated $25.9M.
- Bristol-Myers Squibb made up 0.58% of Natixis's portfolio in Q2 2026, its #25 holding.
- Natixis first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 45 quarters since.
- Natixis's Bristol-Myers Squibb position peaked at $436M in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.